Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sumitomo Pharma America, Inc.
Study will evaluate the efficacy of a new compound versus placebo in the treatment of patients with schizophrenia (diagnosed by DSM-IV criteria) as measured by reductions from baseline on the total score of the Brief Psychiatric Rating Scale (BPRS) as extracted from the Positive and Negative Syndrome Scale (PANSS).
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV
The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment
If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception
You may not be if
The patient has used an investigational drug within the past 30 days
The patient has participated in a previous study of this compound
Clareo Health | A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
